دورية أكاديمية
External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care.
| العنوان: | External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care. |
|---|---|
| المؤلفون: | Sheikh Z; Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom., Potter E; Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom., Li Y; School of Public Health, Nanjing Medical University, Nanjing, China., Drysdale SB; Centre for Neonatal & Paediatric Infection, St George's, University of London, London, United Kingdom., Wildenbeest JG; Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands., Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom., McGinley J; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom., Lin GL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom., Öner D; Infectious Diseases Translational Biomarkers, Janssen Pharmaceutica, Beerse, Belgium., Aerssens J; Infectious Diseases Translational Biomarkers, Janssen Pharmaceutica, Beerse, Belgium., Justicia-Grande AJ; Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, University of Santiago, Santiago de Compostela, Spain., Martinón-Torres F; Department of Pediatrics, Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom., Bont L; Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands., Nair H; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom. |
| المصدر: | The Journal of infectious diseases [J Infect Dis] 2024 Mar 01; Vol. 229 (Supplement_1), pp. S18-S24. |
| نوع المنشور: | Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| مواضيع طبية MeSH: | Secondary Care* , Respiratory Syncytial Virus, Human*, Infant ; Humans ; Case-Control Studies ; Area Under Curve ; Colombia |
| مستخلص: | Background: There is no consensus on how to best quantify disease severity in infants with respiratory syncytial virus (RSV) and/or bronchiolitis; this lack of a sufficiently validated score complicates the provision of clinical care and, the evaluation of trials of therapeutics and vaccines. The ReSVinet score appears to be one of the most promising; however, it is too time consuming to be incorporated into routine clinical care. We aimed to develop and externally validate simplified versions of this score. Methods: Data from a multinational (the Netherlands, Spain, and United Kingdom) multicenter case-control study of infants with RSV were used to develop simplified versions of the ReSVinet score by conducting a grid search to determine the best combination of equally weighted parameters to maximize for the discriminative ability (measured by area under the receiver operating characteristic curve [AUROC]) across a range of outcomes (hospitalization, intensive care unit admission, ventilation requirement). Subsequently discriminative validity of the score for a range of secondary care outcomes was externally validated by secondary analysis of datasets from Rwanda and Colombia. Results: Three candidate simplified scores were identified using the development dataset; they were excellent (AUROC >0.9) at discriminating for a range of outcomes, and their performance was not significantly different from the original ReSVinet score despite having fewer parameters. In the external validation datasets, the simplified scores were moderate to excellent (AUROC, 0.7-1) across a range of outcomes. In all outcomes, except in a single dataset for predicting admission to the high-dependency unit, they performed at least as well as the original ReSVinet score. Conclusions: The candidate simplified scores developed require further external validation in larger datasets, ideally from resource-limited settings before any recommendation regarding their use. Competing Interests: Potential conflicts of interest . Y. L. has received funding from Wellcome Trust and GSK, outside the submitted work, and has received personal fees from Pfizer. S. B. D. has received honoraria from MSD and Sanofi for taking part in respiratory syncytial virus advisory boards and has provided consultancy and/or investigator roles in relation to product development for Janssen, AstraZeneca, Pfizer, Valneva, MSD, iLiAD, and Sanofi, with fees paid to St George's, University of London. J. G. W. participated in an advisory board for Janssen, with fees paid to the University Medical Center Utrecht. D. O. and J. A. are employees of Janssen Pharmaceutica. F. M. T. reports grants from Janssen, MSD, GSK, and AstraZeneca; personal fees from Ablynx, GSK, Pfizer, MSD, Moderna, AstraZeneca, Sanofi-Pasteur, Novavax, Seqirus, and Biofabri; nonfinancial support from GSK, Pfizer, MSD, and Seqirus; and trial fees paid to his institution from all these companies, except Biofabri. A. J. P. is chair of the UK Department of Health and Social Care's Joint Committee on Vaccination and Immunisation. The University of Oxford has entered into a partnership with AstraZeneca for the development of a coronavirus disease 2019 vaccine. L. B. has received funding through the University Medical Center Utrecht from AbbVie, Janssen, the Bill & Melinda Gates Foundation, Nutricia Danon, MeMed Diagnostics, GSK, AstraZeneca, Sanofi, Ablynx, Bavaria Nordic, MabXience, Novavax, and Pfizer. H. N. has received funding from Innovative Medicines Initiative, the National Institute for Health and Care Research, Icosavax and Pfizer and has received fees from GSK, AbbVie, AstraZeneca, Pfizer, Novavax, Sanofi, Merck, Icosavax and ReViral all paid to the insitution. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| معلومات مُعتمدة: | Innovative Medicines Initiative; Horizon 2020; EFPIA |
| فهرسة مساهمة: | Keywords: RSV; severity score; validity |
| تواريخ الأحداث: | Date Created: 20230915 Date Completed: 20240304 Latest Revision: 20240304 |
| رمز التحديث: | 20240304 |
| DOI: | 10.1093/infdis/jiad388 |
| PMID: | 37712125 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiad388 |